Keros Shares Rise 11% After $5 Million Buyback Approval
Keros Therapeutics shares climbed 11% to $11.12 on Tuesday after the company’s board approved a share repurchase program of up to $5 million. The gain followed a $20 million development milestone payment from Takeda Pharmaceuticals under a licensing agreement.
November 17, 2026, 11:45 PM 428 0
The clinical-stage biopharmaceutical company said the payment relates to elritercept, a drug now being tested in a clinical trial. Keros recently completed the first dosing of a patient in the trial.
Despite Tuesday’s rise, the stock remains down 45% this year.
Comments (0)
No comments yet. Be the first!